
News|Articles|July 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 7
- Volume 15
- Issue 7
ChemGenex Launches Trial of Ceflatonin in TKI-Resistant CML
ChemGenex Launches Trial of Ceflatonin in TKI-Resistant CML
Advertisement
MENLO PARK, CalifChem-Genex Pharmaceuticals has launched a multinational phase II/III trial of Ceflatonin (homoharringtonine, HHT) in chronic myeloid leukemia patients who have the T315I bcr-abl point mutation, which makes them resistant to tyrosine kinase inhibitors (TKIs) such as imatinib (Gleevec). In April, FDA granted Ceflatonin orphan drug status for the treatment of CML.
Articles in this issue
almost 20 years ago
High-Quality Screening Colonoscopy Priority for GI Docsalmost 20 years ago
Genentech Seeks Expanded Use of Avastin in Breast Canceralmost 20 years ago
Denosumab Suppresses Bone Resorption in Breast Ca Metsalmost 20 years ago
FDA Approves Priority Review of Merck's Zolinza (Vorinostat)almost 20 years ago
FDA Approves Revlimid for Myeloma Rxalmost 20 years ago
Real-Time RT Planning, Delivery in the Bronxalmost 20 years ago
Phase III Trial of Enzastaurin for NHL Patients Initiatedalmost 20 years ago
Racial Disparities in Prostate Ca RecurrenceNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
MYTHIC Trial Demonstrates Efficacy in Platinum-Resistant Ovarian Cancer
2
Zoldonrasib Shows Promising Activity in KRAS G12D+ NSCLC
3
What is the Future of TIL Therapy in Metastatic Melanoma?
4
Selecting Among Preferred 1L Regimens — A Discussion
5





















































